News and Announcements
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
- Published October 15, 2024 7:42AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.
This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.
Executive Interviews
122% Returns: The Aussie Crypto Fund Outperforming Bitcoin
In the ever-shifting world of cryptocurrency investments, one fund has made waves by consistently outperforming its peers. This fund has demonstrated a remarkable ability to navigate the volatility of the digital asset market while delivering impressive returns. By employing a combination of strategic risk management, selective investing, and benchmarking against Bitcoin, Merkle Tree Capital has […]
Empowering Global Trade: TradeWindow’s Innovative Approach
Dive into an exclusive interview with AJ Smith, Founder & CEO of TradeWindow, as he unveils how TradeWindow is empowering businesses with digital tools to navigate the complexities of global trade. From reducing costs to improving real-time visibility and collaboration, TradeWindow is at the forefront of driving productivity and digital adoption in international trade. Gain […]
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies. Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be […]
Backed By Leading Investment Groups and Family Offices
